LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

• DOI: 10.1016/j.annonc.2023.10.087
• Publication Date: 2023-10-20T13:22:58Z
• Authors: K.N.N. Chi; E. Castro; G. Attard; M.R. Smith; S.K. Sandhu; E. Efstathiou; G. Roubaud; E.J.J. Small; A.J.P.D.S. Gomes; D. Rathkopf; M. Saad; H.P. Gurney; W. Jung; G.E. Mason; S. Dibaj; D. Wu; B. Diorio; A. Lopez-Gitlitz; W. Kim; D. Olmos
• Keywords: Abiraterone acetate; Abiraterone